Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial

This report describes the rationale and design of a study assessing tolvaptan in children with autosomal dominant polycystic kidney disease (ADPKD). Phase A is a 1-year, randomized, double-blind, placebo-controlled, multicenter trial. Phase B is a 2-year, open-label extension. The target population...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaefer, Franz, Mekahli, Djalila, Emma, Francesco, Gilbert, Rodney D., Bockenhauer, Detlef, Cadnapaphornchai, Melissa A., Shi, Lily, Dandurand, Ann, Sikes, Kimberly, Shoaf, Susan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565642/
https://www.ncbi.nlm.nih.gov/pubmed/31053954
http://dx.doi.org/10.1007/s00431-019-03384-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565642/
https://www.ncbi.nlm.nih.gov/pubmed/31053954
http://dx.doi.org/10.1007/s00431-019-03384-x

Ejemplares similares